Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide

Annelies Noorlander*, Eric Fabian, Bennard van Ravenzwaay, Ivonne M.C.M. Rietjens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The aim of the present study was to develop a generic rat physiologically based kinetic (PBK) model that includes a novel testing strategy where active biliary excretion is incorporated using estradiol-17β glucuronide (E217βG) as the model substance. A major challenge was the definition of the scaling factor for the in vitro to in vivo conversion of the PBK-model parameter Vmax. In vitro values for the Vmax and Km for transport of E217βG were found in the literature in four different studies based on experiments with primary rat hepatocytes. The required scaling factor was defined based on fitting the PBK model-based predicted values to reported experimental data on E217βG blood levels and cumulative biliary E217βG excretion. This resulted in a scaling factor of 129 mg protein/g liver. With this scaling factor the PBK model predicted the in vivo data for blood and cumulative biliary E217βG levels with on average of less than 1.8-fold deviation. The study provides a proof of principle on how biliary excretion can be included in a generic PBK model using primary hepatocytes to define the kinetic parameters that describe the biliary excretion.

Original languageEnglish
Pages (from-to)91-102
JournalArchives of Toxicology
Volume95
Early online date7 Nov 2020
DOIs
Publication statusPublished - Jan 2021

Keywords

  • Biliary excretion
  • Physiologically based kinetic modelling
  • Primary rat hepatocytes
  • Scaling factor

Fingerprint Dive into the research topics of 'Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide'. Together they form a unique fingerprint.

Cite this